Shandong Chenming Paper (01812): Abnormal fluctuations in the trading of A shares and B shares, there is no undisclosed information that should be disclosed.
Morning Paper Industry (01812) issues announcement, A-share stock (stock code: 000488, stock abbreviation: ST Morning...
Shandong Chenming Paper (01812) announced that the trading prices of its A-share stock (stock code: 000488, stock abbreviation: ST Chenming) and B-share stock (stock code: 200488, stock abbreviation: ST Chenming B) consecutively declined by more than 12% on February 21, 2025, February 24, 2025, and February 25, 2025. According to the relevant provisions of the Shenzhen Stock Exchange Stock Trading Rules, this constitutes abnormal volatility in stock trading.
The board of directors confirmed that the company currently does not have any undisclosed matters or related planning, discussions, intentions, agreements, etc. that should be disclosed in accordance with the Shenzhen Stock Exchange Stock Listing Rules. The board of directors also did not receive any information that should be disclosed according to the relevant rules that would have a significant impact on the trading prices of the company's stock and its derivative products. There is no need to correct or supplement the information disclosed by the company in the past.
Related Articles

CLOUDBREAK-B (02592) awarded 4.2842 million restricted stock units.

Huatai (06886): The face interest rate for the public offering of subordinated bonds (third tranche) for professional investors in 2025 is 2.24%.

US Stock Market Move | HSAI.US rose by 3%, receiving an increase in institutional forecasts for next year's revenue and net profit.
CLOUDBREAK-B (02592) awarded 4.2842 million restricted stock units.

Huatai (06886): The face interest rate for the public offering of subordinated bonds (third tranche) for professional investors in 2025 is 2.24%.

US Stock Market Move | HSAI.US rose by 3%, receiving an increase in institutional forecasts for next year's revenue and net profit.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025